The IL-2 group had early significantly higher proportions of SRI-4 responders than the placebo group and up to week 24 (29% difference) and 54% of the patients in a subgroup with lupus nephritis had a complete renal response at week 12 vs. 8% in the placebo group. This evidence concerns the gene IL2 and lupus nephritis.